Search

Displaying results 5011 - 5020 of 10000 in total
  1. Drug

    MDX-214

    go.drugbank.com/drugs/DB06110
    Experimental

    It is developed for the treatment of EGF-R overexpressing cancers. … MDX-214 consists of recombinant human epidermal growth factor (EGF) genetically linked to a fully human antibody fragment that is designed to activate cytotoxic killing of cancer cells by immune effector

  2. Drug

    Irampanel

    go.drugbank.com/drugs/DB21123
    Investigational

    Irampanel is under investigation in clinical trial NCT02222961 (Single Increasing Dose Followed by Maintenance Dose Tolerance Study of BIIR 561 CL in Healthy Male Volunteers). … Irampanel is a small molecule drug.

  3. Drug

    Oxilofrine

    go.drugbank.com/drugs/DB11610
    Approved

    Oxilofrine is used in combination with [DB11609] as an antitussive. It is currently marketed in Canada by Valeant under the tradename Cophylac.

  4. Drug

    EMZ702

    go.drugbank.com/drugs/DB05021
    Investigational

    EMZ702 has an excellent safety profile and the combination of EMZ702 with interferon and ribavirin in surrogate models for hepatitis C has demonstrated a two to three fold increase in anti-viral potency … EMZ702, a non-toxic agent that has strong anti-viral synergy with interferon, is an ideal candidate for combination with current standard hepatitis C treatments.

  5. Drug

    Coenzyme A

    go.drugbank.com/drugs/DB01992
    InvestigationalNutraceutical

    Coenzyme A (CoA, CoASH, or HSCoA) is a coenzyme, well known for it's role in the synthesis and oxidation of fatty acids, and the oxidation of pyruvate in the citric acid cycle. … All genomes sequenced to date encode enzymes that use coenzyme A as a substrate, and around 4% of cellular enzymes use it, or a thioester form of it, as a substrate.

  6. Drug

    PSN9301

    go.drugbank.com/drugs/DB05001
    Experimental

    PSN9301 is an oral small molecule inhibitor of Dipeptidyl Peptidase IV (DP-IV), being developed for the treatment of type 2 diabetes. … PSN9301 has a very rapid onset and a relatively short duration of action, and available pre-clinical and clinical data indicate that it may be an ideal product candidate for meal-related dosing.

  7. Drug

    Oxandrolone

    go.drugbank.com/drugs/DB00621
    ApprovedInvestigational

    A synthetic hormone with anabolic and androgenic properties.

    Categories: Anabolic Agents for Systemic Use
  8. Drug

    Meplazumab

    go.drugbank.com/drugs/DB16465
    Investigational

    Meplazumab is a humanized anti-CD147 antibody being investigated as an add-on therapy in patients with COVID-19 pneumonia.

    Categories: Experimental Unapproved Treatments for COVID-19
  9. Drug

    Chlorphentermine

    go.drugbank.com/drugs/DB01556
    ApprovedIllicitWithdrawn

    A sympathomimetic agent that was formerly used as an anorectic. It has properties similar to those of dextroamphetamine. It has been implicated in lipid storage disorders and pulmonary hypertension.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  10. Drug

    Zytron

    go.drugbank.com/drugs/DB11768
    ApprovedWithdrawn

    Zytron (DMPA) is under investigation for the treatment and health services research of HIV, Lactation, Contraception, Postpartum Depression, and Immune Cells (Mucosal and Systemic). … DMPA has been investigated for the prevention, treatment, and basic science of Weight and Microbiota.

    Synonyms: O-(2,4-dichlorophenyl)-O-methyl-isopropylphosphoramidothioate